Vestibular migraine may be a relatively new diagnostic entity, but a new study shows it impacts around 6 million US adults.
Investigational Oral Agent ALZ-801 Slows Brain Atrophy and Cognitive Decline in APOE4 Homozygotes with Early AD
Valiltramiprosate is a novel disease modifying therapy designed to inhibit formation of soluble neurotoxic amyloid oligomers, acting upstream in the amyloid cascade.
The Weekly Dose: Pediatric Vaccine Safety, Atopic Dermatitis, Dementia Risk, and Maternal Depression
Insights on atopic dermatitis treatment preferences, the safety of childhood vaccines, maternal depression’s effect on parenting, and more.
Benzodiazepine, Antipsychotic Use Linked to Increased Mortality in Hospice Patients With Dementia
A study reveals that starting benzodiazepines or antipsychotics in hospice patients with dementia significantly increases 180-day mortality, urging careful prescribing.
Make It Routine: Screening for Cognitive Decline in Primary Care
Listen to our latest podcast episode to discover how early dementia detection enhances care and quality of life, with actionable strategies for primary care teams to implement now.
FDA Clears First Blood Test to Rule Out Alzheimer-Related Pathology in Primary Care
Roche's Elecsys pTau181 test has a 97.9% negative predictive value to rule out amyloid pathology, which will improve referral decisions and expedite treatment.
Open-Label Placebos Show Mixed Results in Migraine Prevention Trial
OLPs did not affect migraine frequency but did subjectively improve QoL, with authors noting they may have a role as a supportive treatment option for select patients.